DOV Pharmaceutical

Quality 0.50 · 0 views · Updated 2 months ago

Biotechnology company acquired in 2010

title: "DOV Pharmaceutical" type: doc version: 1 created: 2026-02-28 author: "Wikipedia contributors" status: active scope: public tags: ["biotechnology-companies-of-the-united-states", "companies-based-in-bergen-county,-new-jersey", "pharmaceutical-companies-based-in-new-jersey", "biotechnology-companies-established-in-1995", "1995-establishments-in-new-jersey", "biotechnology-companies-disestablished-in-2010", "2010-disestablishments-in-new-jersey", "american-companies-established-in-1995"] description: "Biotechnology company acquired in 2010" topic_path: "geography/united-states" source: "https://en.wikipedia.org/wiki/DOV_Pharmaceutical" license: "CC BY-SA 4.0" wikipedia_page_id: 0 wikipedia_revision_id: 0

::summary Biotechnology company acquired in 2010 ::

DOV Pharmaceutical was a biotechnology company that focused on therapies primarily for central nervous system conditions. It was founded in 1995 by former employees of American Cyanamid (which was acquired by Wyeth in 1994), and in 1998 it in-licensed drugs discovered at American Cyanamid for further development. It held an IPO on NASDQ in 2002, and its shares plunged days later after negative details about a past relationship between Élan and DOV emerged.Hess, Diane, Drugmaker's IPO Is a Big Headache , TheStreet.com, 1 May 2002. Retrieved 5 November 2007.

Phil Skolnick served as CSO from 2001 to 2009. Euthymics had been founded by Anthony McKinney and Frank Bymaster, a chemist who had worked at Eli Lilly on discovery and development of Prozac, Cymbalta, and Symbyax; the company was funded with $24 million from Novartis Venture Funds among others.

After several failed clinical trials, in 2010 Dov was acquired by Euthymics Bioscience which intended to continue development of Dov's antidepressant, amitifadine (DOV 21,947, renamed EB-1010).

Its drug candidates included:

  • Indiplon for insomnia, licensed from Wyeth in 1998, which it licensed to Neurocrine Biosciences in 1998.
  • Bicifadine, a triple-uptake inhibitor for pain, licensed from Wyeth in 1998,
  • Triple-uptake inhibitors for depression and related psychiatric disorders: (DOV 21,947 and DOV 216,303) licensed from Wyeth in 1998. Merck sublicensed the rights in 2004, and terminated them in 2006.
  • Ocinaplon for anxiety disorders.
  • A proprietary formulation of diltiazem
  • DOV 102,677, for the treatment of Parkinson's disease, restless leg syndrome, attention deficit disorder
  • DOV 51,892, for anxiety disorders
  • DOV-216,303, the racemic mixture that included amitifadine, which was discontinued after the patent covering it expired.

References

References

  1. Neubauer, DN. "Indiplon". pp 453-464 in GABA and Sleep: Molecular, Functional and Clinical Aspects. Eds Jaime M. Monti, Seithikurippu Ratnas Pandi-Perumal, Hanns Möhler. Springer Science & Business Media, 2010 {{ISBN. 9783034602266
  2. link. (15 July 2015 Page accessed 15 July 2015)
  3. Krauskopf, Lewis, [https://web.archive.org/web/20110516211629/http://www.highbeam.com/doc/1G1-85388878.html Investors Suing Hackensack, N.J.-Based DOV Pharmaceutical over Stock Losses], [[The Record (Bergen County). The Record (Hackensack, New Jersey)]], 2 May 2002. Retrieved 5 November 2007
  4. Maeillo, Michael, [http://www.mywire.com/pubs/Forbes/2002/09/02/198776?extID=10051 The Coldest IPO...], [[Forbes.com]], 2 September 2002. Retrieved 5 November 2007
  5. [https://money.cnn.com/2002/04/25/markets/ipo/ipo/ DOV IPO sinks on first day], [[CNN.com]], 25 April 2002. Retrieved 5 November 2007
  6. (1 April 2010). "Press Release: Dr. Phil Skolnick Now Leads NIDA's Medications Development Efforts". National Institute on Drug Abuse.
  7. (5 July 2006). "Press Release: DOV Pharmaceutical, Inc. Announces Reorganization of Senior Management". DOV Pharmaceutical via PRNewswire.
  8. (12 March 2012). "Happy Results for a Depression Drug". Chemical & Engineering News Archive.
  9. Fierce Biotech 22 July 2010 [http://www.fiercebiotech.com/story/euthymics-lands-24m-fund-antidepressant-work/2010-07-22 Euthymics lands $24M to fund antidepressant work]
  10. (5 September 2010). "Oklahoma attorney helps with Mass. bioscience startup". NewsOK.com.
  11. [https://www.sec.gov/Archives/edgar/data/1066833/000114420404018172/v08017_ex10-51.txt [https://www.sec.gov/Archives/edgar/data/1066833/000114420404018172/v08017_ex10-51.txt SEC Filing: Wyeth-DOV Restated License Agreement] Page accessed July 15, 2015]
  12. (Sep 2008). "Triple reuptake inhibitors: a premise and promise". Psychiatry Investig.
  13. Chemical and Engineering News. 12 August 2004 [http://pubs.acs.org/cen/news/8232/8232earlybuscon2.html Merck and DOV Pharmaceutical In Drug Pact]
  14. Dov 8 December 2006 [http://www.biospace.com/News/dov-pharmaceutical-announces-termination-of/39450 DOV Pharmaceutical Announces Termination Of License Agreement With Merck & Co., Inc. (MRK)]
  15. link. (15 July 2015 Page accessed 15 July 2015)
  16. (31 March 2008). "10-K For the fiscal year ended December 31, 2007". Dov Pharmaceutical via SEC Edgar.

::callout[type=info title="Wikipedia Source"] This article was imported from Wikipedia and is available under the Creative Commons Attribution-ShareAlike 4.0 License. Content has been adapted to SurfDoc format. Original contributors can be found on the article history page. ::

biotechnology-companies-of-the-united-statescompanies-based-in-bergen-county,-new-jerseypharmaceutical-companies-based-in-new-jerseybiotechnology-companies-established-in-19951995-establishments-in-new-jerseybiotechnology-companies-disestablished-in-20102010-disestablishments-in-new-jerseyamerican-companies-established-in-1995